Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Revenue Beat
REGN - Stock Analysis
3993 Comments
1214 Likes
1
Dionnie
Experienced Member
2 hours ago
This kind of delay always costs something.
👍 179
Reply
2
Tramar
Elite Member
5 hours ago
Free US stock correlation to major indices and sector benchmarks for performance attribution analysis. We help you understand how your portfolio moves relative to broader market benchmarks.
👍 124
Reply
3
Princejohn
Consistent User
1 day ago
Short-term pullback could be expected after the recent rally.
👍 216
Reply
4
Jaimz
New Visitor
1 day ago
Offers a good mix of high-level overview and specific insights.
👍 144
Reply
5
Kale
Active Contributor
2 days ago
Free US stock macro sensitivity analysis and sector exposure assessment for economic condition positioning. We help you understand which types of stocks perform best under different economic scenarios.
👍 209
Reply
© 2026 Market Analysis. All data is for informational purposes only.